Routed from your metabolism signal. 2 vendors scored against the published 11-signal rubric. The honest version of the peptide decision.
Your primary signal points to metabolism. Tirzepatide is the lead compound for this route, and the trial data is what backs it.
Three checkpoints along the SURMOUNT-1 time course. Trial-average numbers, not a forecast for you. Your actual curve depends on dose tolerance, adherence, and what you do outside the injection.
The dose is still climbing. Nausea tends to peak here, then ease as your receptors adjust. Most quits happen this month.
You feel it without weighing in. Clothes sit differently. Many reach their dose plateau here. The signal is now more behavioral than pharmacological.
The trial endpoint. Mean across the top dose arm. How much of that is fat versus lean mass is decided almost entirely by protein intake and resistance training.
Trial context: 91% of the 15 mg arm passed 5% weight loss. 57% passed 20%. Where you land depends on effort, adherence, and biology. Jastreboff AM et al. SURMOUNT-1, NEJM 2022.
Tirzepatide is tirzepatide. The difference between 1,350 and 180 is geography, distribution, and whether a US pharmacy benefit manager is between you and the molecule. If you can travel or ship from Thailand, you pay a fraction.
10 mg monthly, often insurance-gated, Eli Lilly list price.
503A compounding pharmacy, prescription required, state-by-state variance.
NHS rarely covers. Boots, Pharmacy2U, etc.
Same FDA-approved Lilly molecule, imported, doctor-prescribed, clinic-pickup or delivery.
No consultation, more user responsibility, vendor-quality-dependent.
Ranges reflect public vendor pricing April 2026. Your actual number depends on dose progression and any consultation fees. The Panya match names the vendor and cites the current invoice.
Dual GIP and GLP-1 receptor agonist, once-weekly injection. Approved for chronic weight management on the strength of SURMOUNT-1 and for type 2 diabetes on SURPASS. Below: what the primary trial data says, what the mechanism actually is, and three caveats the marketing tends to skip.
How often the trial participants hit each weight-loss threshold. Placebo arm is the baseline; 15 mg is the top dose. Numbers marked "approx." are read from the NEJM figures rather than the primary tables.
| Weight-loss threshold | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| ≥5% | 35% | 85% | 89% | 91% |
| ≥10%approx. | 19% | 69% | 78% | 84% |
| ≥15%approx. | 9% | 50% | 64% | 71% |
| ≥20% | 3% | 30% | 50% | 57% |
| ≥25% | 2% | 15% | 32% | 36% |
Tirzepatide binds the GIP receptor with higher affinity than the GLP-1 receptor. At GLP-1 it is a biased agonist favoring cAMP signaling over β-arrestin recruitment, which means slower receptor desensitization than native GLP-1. Translation: it engages GLP-1 signaling without burning out the receptor as quickly.
[5] JCI Insight, 2020GIP receptor activation in adipose tissue improves glucose disposal and lipid handling. Phase 2 data showed insulin sensitivity improvements only partly attributable to weight loss, suggesting a direct tissue effect independent of the appetite pathway.
[5] JCI Insight, 2020A fatty-diacid side chain gives tirzepatide a ~5-day half-life through high-affinity albumin binding. That is why it dosed once weekly rather than daily.
[5] JCI Insight, 2020GI events dominate, heaviest in the first weeks of dose escalation. Pancreatitis incidence stays within placebo range across dose arms when adjudicated.
| Event | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 9.5% | 24.6% | 33.3% | 31.0% |
| Diarrhea | 7.3% | 18.7% | 21.2% | 23.0% |
| Discontinuation from adverse event | 2.6% | 4.3% | 7.1% | 6.2% |
| Pancreatitis (adjudicated) | 0.4% | 0.2-0.4% | 0.2-0.4% | 0.2-0.4% |
In SURMOUNT-4, 82.5% of people who stopped tirzepatide regained at least a quarter of the weight they had lost within a year. Cardiometabolic improvements partially reversed in proportion to regain. Practical read: this is long-term medication, not a course of treatment.
[2] JAMA, 2023In the SURMOUNT-1 body-composition substudy, roughly 74% of weight loss was fat mass and 26% was lean mass. On 15mg the absolute lean-mass loss is 5 to 6 kg. Protein intake and resistance training are not optional on this compound.
[4] Diabetes, Obesity and Metabolism, 2025In a US real-world registry of ~21,000 patients, six-month persistence was 55%. Top reasons for stopping: cost (48%), side effects (15%), shortage or supply gaps (12%). Trial populations are selected. General-population experience is not.
[3] Diabetes, Obesity and Metabolism, 2025“If you are taking these drugs, really pay attention to your protein consumption and your resistance training. That is going to be an important part of being on the right side of that body-composition curve.”
“Dual GIP and GLP-1 agonism is the current state of the art, and muscle loss is the primary near-term concern the next generation of compounds is being designed to offset.”
If any of the below applies, tirzepatide is either off the table or needs a clinician in the loop before a vendor. We are a matchmaker, not a prescriber. Naming this up front is the job.
Not medical advice. This is the shortlist we check against before matching. If anything on it applies to you, the next click is a clinician, not a vendor.
Observational, not prescriptive. The questions people in your goal cluster tend to ask once they are past the quiz.
Your email unlocks the full write-up from our Vendor-Match Agent. Names, pricing, lead times, shipping posture.
Bangkok clinic, peptide-forward practice, ISO/GMP facility, named clinicians with verified credentials.
Vendor name, current pricing, direct contact. No list, no drip.
Bangkok-based direct vendor, COA on request, same-day moto courier in-city, EMS 1 to 2 days domestic.
Vendor name, current pricing, direct contact. No list, no drip.
Panya considered every vendor in the Phase 1 roster against your quiz profile. Here is the non-redacted breakdown of why the vendors that did not appear in your top 2 were filtered:
Names redacted for the 19 only when publication carries defamation risk. When evidence is public (regulatory action, conviction, closure), the vendor appears by name on our filter page.
Most matchmakers hide the reasoning behind the recommendation. Here is what Panya actually did for your match, step by step. Deterministic output from your 5 quiz signals and our vendor database. No LLM slop, no black box.
goal=metabolic · urgency=n/a · budget=n/a · region=your region
vendors evaluated against the 11-signal public rubric
FDA action · conviction · permanent closure · review-forensics failure
Import rules, prescription posture, cold-chain feasibility for your region
Price band intersection with user-selected budget signal
Signals weighted: identity (×3), cold-chain (×3), COA (×2), response time (×2), else ×1
Panya started from 72 scored vendors, filtered to 5 that fit your profile, ranked by rubric trust signal, and surfaced the 2 you see above.
Same trace logic every time · Zero paid placement · Full methodology at /methodology
You share your Panya link with a friend who's researching peptides.
They take the quiz, get matched, and pay the vendor through Panya.
Panya earns an affiliate commission from that vendor (each vendor's rate differs — we publish them at /margins).
50% of whatever Panya actually earns becomes your credit, applied to your own cost next month. The split is fixed; the dollar amount tracks the vendor.
Peptides that used to cost $1,200+/mo shouldn't only be for people with money. Panya Access turns the tool itself into the access path. When a friend finds their match through you, you earn credit against your own cost.
Numbers assume an average commission rate. Actual credit varies by vendor — forecasts, not quotes.
No MLM. No downline. No cash sales pitch for you to push. You share the tool you actually used — and if your friend converts, the math works for both of you.
https://panya.health/Credit ledger launches next release. Every share you make from today forward counts retroactively.
Here is exactly what lands in your inbox, in the order it lands. No follow-up drip. No upsell sequence. No partner emails.
Quick confirm. We received your metabolism-signal submission. A human is reviewing the Vendor-Match Agent draft right now. Expect the full match within 48 hours.
Two vendors reviewed against the 11-signal rubric. Your primary match, score 00/100, plus one line on why this one fits your profile. A second vendor as backup if the primary is not right for you. Pricing posture, direct contact, and the honest tradeoffs. No more emails after this.
That is it. No drip. No list.
The rubric score, what each vendor failed on, and the cheaper alternative if there is one. One email. No list.
We email the match, then stop. No drip. No partner emails.
Your personal link carries a discount for whoever uses it. Friend takes the quiz, gets their own match, pays less than cold on their first order. When they buy, you earn commission as credit toward your own next order. The specific numbers arrive with your match email and depend on the vendor.
The personal code arrives with your email unlock. Until then, the generic link works.
LINE for Thailand. WhatsApp for Scandi and EU. X if you want to tell the internet.
When they finish the quiz with your link, you become a founding member. No cash, no points, no spam. Just a badge on the result page and a first-access invite when we open Concierge.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.
Panya holds no inventory and earns a flat referral rate regardless of which vendor you pick. We do not get paid more for recommending a more expensive vendor. That is the core of the trust-first model and the entire reason Panya exists.